Parvus Therapeutics
Clinical-stage biopharmaceutical company developing peptide–MHC (pMHC) nanomedicine candidates that induce antigen-specific regulatory T cells in vivo to restore organ-specific immune tolerance. The company advances preclinical programs into early clinical studies, manages CMC and GMP scale-up through CDMO partnerships, and structures licensing and development collaborations with large pharmaceutical partners.
Industries
N/A
Products
PVT201
A peptide–MHC (pMHC) nanomedicine candidate composed of multiple copies of a pMHC conjugated to an iron-dextran nanoparticle, developed for autoimmune liver diseases; advanced into first-in-human studies and granted FDA Orphan Drug designation for primary biliary cholangitis.
PVT401
A peptide–MHC (pMHC) nanomedicine candidate in development for inflammatory bowel disease; progressed through nonclinical pharmacology and manufacturing criteria toward IND-enabling activities under a collaboration agreement with a major pharmaceutical partner.
PVT201
A peptide–MHC (pMHC) nanomedicine candidate composed of multiple copies of a pMHC conjugated to an iron-dextran nanoparticle, developed for autoimmune liver diseases; advanced into first-in-human studies and granted FDA Orphan Drug designation for primary biliary cholangitis.
PVT401
A peptide–MHC (pMHC) nanomedicine candidate in development for inflammatory bowel disease; progressed through nonclinical pharmacology and manufacturing criteria toward IND-enabling activities under a collaboration agreement with a major pharmaceutical partner.
Services
Preclinical development and IND-enabling studies
Conduct of nonclinical pharmacology, safety and mechanism-of-action studies to support regulatory filings.
CMC and GMP tech transfer with CDMOs
Technology transfer and scale-up of nanoparticle and pMHC protein production with contract manufacturing partners to produce clinical and GMP material, including conjugation and fill/finish services.
Early clinical development and trial operations
Execution of early-phase clinical studies including safety, PK/PD and biomarker endpoints for nanomedicine candidates.
Preclinical development and IND-enabling studies
Conduct of nonclinical pharmacology, safety and mechanism-of-action studies to support regulatory filings.
CMC and GMP tech transfer with CDMOs
Technology transfer and scale-up of nanoparticle and pMHC protein production with contract manufacturing partners to produce clinical and GMP material, including conjugation and fill/finish services.
Early clinical development and trial operations
Execution of early-phase clinical studies including safety, PK/PD and biomarker endpoints for nanomedicine candidates.
Expertise Areas
- Antigen-specific immunotherapy development
- In vivo regulatory T‑cell (Treg) induction and translational immunology
- Nanoparticle-based drug design and scale-up
- Preclinical in vivo disease modeling and mechanism-of-action studies
Key Technologies
- Peptide–MHC complexes
- Polymer-coated iron-oxide nanoparticles
- Nanoparticle–protein conjugation chemistry
- CHO mammalian cell expression systems